ATE135582T1 - Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen - Google Patents

Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen

Info

Publication number
ATE135582T1
ATE135582T1 AT91114034T AT91114034T ATE135582T1 AT E135582 T1 ATE135582 T1 AT E135582T1 AT 91114034 T AT91114034 T AT 91114034T AT 91114034 T AT91114034 T AT 91114034T AT E135582 T1 ATE135582 T1 AT E135582T1
Authority
AT
Austria
Prior art keywords
bismuth
pref
antimicrobial
days
administered
Prior art date
Application number
AT91114034T
Other languages
English (en)
Inventor
Barry James Marshall
Original Assignee
Barry James Marshall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barry James Marshall filed Critical Barry James Marshall
Application granted granted Critical
Publication of ATE135582T1 publication Critical patent/ATE135582T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91114034T 1985-06-13 1986-06-10 Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen ATE135582T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74484185A 1985-06-13 1985-06-13

Publications (1)

Publication Number Publication Date
ATE135582T1 true ATE135582T1 (de) 1996-04-15

Family

ID=24994175

Family Applications (3)

Application Number Title Priority Date Filing Date
AT91114034T ATE135582T1 (de) 1985-06-13 1986-06-10 Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
AT86304407T ATE81010T1 (de) 1985-06-13 1986-06-10 Zusammensetzungen zur behandlung von magendarmst¯rungen.
AT95112838T ATE318144T1 (de) 1985-06-13 1986-06-10 Pharmazeutische zusammensetzung zur behandlung gastrointestinaler beschwerden, die wismut und ein antimikrobielles mittel enthält

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT86304407T ATE81010T1 (de) 1985-06-13 1986-06-10 Zusammensetzungen zur behandlung von magendarmst¯rungen.
AT95112838T ATE318144T1 (de) 1985-06-13 1986-06-10 Pharmazeutische zusammensetzung zur behandlung gastrointestinaler beschwerden, die wismut und ein antimikrobielles mittel enthält

Country Status (11)

Country Link
EP (3) EP0206625B1 (de)
JP (1) JPH0794390B2 (de)
AT (3) ATE135582T1 (de)
AU (1) AU588601B2 (de)
BE (1) BE904921A (de)
CA (1) CA1277232C (de)
DE (4) DE3686836T2 (de)
IE (1) IE59583B1 (de)
NZ (1) NZ216516A (de)
PH (1) PH25288A (de)
ZA (1) ZA864449B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62502967A (ja) * 1985-04-18 1987-11-26 ザ・プロクター・アンド・ギャンブル・カンパニー 非潰瘍消化不良症の治療
US4959384A (en) * 1985-10-24 1990-09-25 Norwich Eaton Pharmaceuticals, Inc. Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
DE3874917T2 (de) * 1987-03-09 1993-03-04 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
EP0439453B1 (de) * 1987-10-12 1994-01-19 Exomed Australia Pty. Ltd. (ACN 051 976 446) Behandlungsverfahren für magen-darm-krankheiten
GB8817098D0 (en) * 1988-07-18 1988-08-24 Glaxo Group Ltd Chemical compounds
EP0363502B1 (de) * 1988-10-08 1991-09-25 Dr. R. Pfleger Chemische Fabrik Gmbh Flüssiges, wismuthaltiges Arzneipräparat, Verfahren zum Herstellen desselben und seine Verwendung
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
EP0375068A1 (de) * 1988-12-23 1990-06-27 Gist-Brocades N.V. Mischungen von Bismuth-Verbindungen und Tetracyclinen
DE3901508C2 (de) * 1989-01-19 1994-04-07 Falk Pharma Gmbh Arzneimittel auf der Grundlage eines Wismut enthaltenden Präparats in fester Form
FI910088A7 (fi) * 1990-01-09 1991-07-10 Brocades Pharma Bv Oraalinen farmaseuttinen koostumus
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
CA2113614A1 (en) * 1991-07-24 1993-02-04 Scott Donald Whalen Antimicrobial treatment methods and compositions
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
WO1995008332A1 (en) * 1993-09-20 1995-03-30 The Procter & Gamble Company Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
FR2715067B1 (fr) * 1994-01-14 1996-04-05 Ethypharm Lab Prod Ethiques Nouvelle forme galénique de dérivés de 5-nitro-imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus gastro-intestinal.
US5549911A (en) * 1994-01-14 1996-08-27 Laboratoires Des Produits Ethiques Ethypharm Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract
GB2293323A (en) * 1994-09-12 1996-03-27 Orion Yhtymae Oy Antibiotics and bismuth salts for treating bacterial infections
GB2292884A (en) * 1994-09-12 1996-03-13 Orion Yhtymae Oy Rifamycin & bismuth salts for treating bacterial infections
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
PE48297A1 (es) * 1995-05-09 1998-02-04 Procter & Gamble Metodos y composiciones para la prevencion y el tratamiento de desordenes gastrointestinales
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US5702729A (en) * 1995-12-07 1997-12-30 The Procter & Gamble Company Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria
US6051604A (en) * 1995-12-07 2000-04-18 The Proctor & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US6067989A (en) * 1997-02-26 2000-05-30 Oridion Medical, Ltd. Breath test for the diagnosis of Helicobacter pylori infection in the gastrointestinal tract
US6186958B1 (en) 1997-02-26 2001-02-13 Oridion Medical Breath test analyzer
USRE38728E1 (en) * 1997-09-11 2005-04-19 Oridion Medical, LTD Breath test analyzer
KR100572090B1 (ko) * 1998-02-24 2006-04-17 액티브 바이오틱스 인코포레이티드 상승작용이 있는 항균제 조성물, 그것을 함유하는 의약 및 소화기질환 치료제, 그들의 제조 방법, 및 그에 관련된 제제
DE19850445A1 (de) * 1998-11-02 2000-05-04 Falk Pharma Gmbh Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
CN104666429A (zh) * 2013-11-28 2015-06-03 天津瑞贝特科技发展有限公司 治疗鸡腺胃炎的组合物及其制备方法
CA2959414C (en) 2014-09-05 2023-03-14 Symbiomix Therapeutics, Llc Secnidazole for use in the treatment of bacterial vaginosis
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1332522A (fr) * 1961-10-05 1963-07-19 Procédé pour préparer des composés résultant de la combinaison chimique de substances antibiotiques et de substances mycocides
US3395212A (en) * 1964-08-10 1968-07-30 American Cyanamid Co Neomycin and organobismuth antibacterial finish for cellulosic material
FR6531M (de) * 1967-09-14 1968-12-09
US4153685A (en) * 1968-11-23 1979-05-08 Schering Corporation Bismuth complex preparations
FR2053002A1 (en) * 1969-06-21 1971-04-16 Clin Midy Bismuth slats of alpha methiminobenzyl - penicillin
DE1963496A1 (de) * 1969-12-18 1971-06-24 Hans Voigt Chemisch Pharmazeut Pharmazeutisches Praeparat zur Behandlung von Magen-Darm-Erkrankungen
US4118480A (en) * 1973-02-09 1978-10-03 Charles V. Stoelker Pharmaceutical preparation for treating hemorrhoids and anal fissures
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
ZA74385B (en) * 1974-01-18 1975-08-27 Gist Brocades Nv Pharmaceutical compositions
US4016268A (en) * 1975-10-06 1977-04-05 Morton-Norwich Products, Inc. Method of combatting gastric ulceration
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
PT75550B (en) * 1981-09-22 1984-12-12 Gist Brocades Nv Bismuth containing composition and method for the preparation thereof
US4588589A (en) * 1983-10-13 1986-05-13 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
JPS62502967A (ja) * 1985-04-18 1987-11-26 ザ・プロクター・アンド・ギャンブル・カンパニー 非潰瘍消化不良症の治療

Also Published As

Publication number Publication date
EP0462631A1 (de) 1991-12-27
EP0206625B1 (de) 1992-09-30
AU588601B2 (en) 1989-09-21
CA1277232C (en) 1990-12-04
DE3650787D1 (de) 2006-04-27
DE3686836D1 (de) 1992-11-05
DE3650787T2 (de) 2006-11-16
DE3619702A1 (de) 1987-02-12
NZ216516A (en) 1989-08-29
BE904921A (fr) 1986-12-15
EP0707854A3 (de) 1997-06-04
PH25288A (en) 1991-04-30
ATE81010T1 (de) 1992-10-15
EP0462631B1 (de) 1996-03-20
AU5859586A (en) 1986-12-18
ATE318144T1 (de) 2006-03-15
DE3650504T2 (de) 1996-10-31
JPH0794390B2 (ja) 1995-10-11
DE3686836T2 (de) 1993-03-04
JPS6248623A (ja) 1987-03-03
IE861572L (en) 1986-12-13
EP0206625A3 (en) 1989-04-05
EP0707854A2 (de) 1996-04-24
ZA864449B (en) 1987-02-25
EP0707854B1 (de) 2006-02-22
DE3650504D1 (de) 1996-04-25
IE59583B1 (en) 1994-03-09
EP0206625A2 (de) 1986-12-30

Similar Documents

Publication Publication Date Title
ATE135582T1 (de) Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
Graham et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomized controlled trial
US5256684A (en) Methods and compositions for the treatment of gastrointestinal disorders
AU590578B2 (en) Treatment of non-ulcer dyspepsia with bismuth salts
KR880010768A (ko) 위장장해의 치료 및 예방용 약제학적 조성물
KR880011197A (ko) 위장장해를 치료하기 위한 조성물 및 방법
DE69125940T2 (de) Pharmazeutische zusammensetzungen die 5-difluormethoxy-2-[3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
EP0865286B1 (de) Bismut und antimikrobielle mittel enthaltende zusammensetzung zur verhütung und behandlung gastrointestinaler beschwerden
US4252821A (en) Method for treating ulcers
Goodwin The susceptibility of Helicobacter pylori to antibiotics
Lambert Effect of Antiulcer drugs on Helicobacter pylori
Gardikas et al. Cefuroxime in the treatment of urinary tract infections
Evans Jr et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing
Scarpignato et al. H2 Receptor Antagonists: Is There a Place in the Treatment of Helicobacter pylori Infection?
Price et al. The urinary excretion of penicillins G and K in rabbits
Goodwin Antibiotics in Helicobacter pylori Treatment
Hutchinson Treatment of streptococcal pharrngitis revisited: Bass JW. JAMA. 1986; 256: 740–743
WO1997020566A1 (en) Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders
RU97111830A (ru) Соединения для ингибирования секреции желудочной кислоты

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time